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Abstract
Multiple factors underlie susceptibility to essential hypertension, including a significant genetic and ethnic component, and
environmental effects. Blood pressure response of hypertensive individuals to salt is heterogeneous, but salt sensitivity
appears more prevalent in people of indigenous African origin. The underlying genetics of salt-sensitive hypertension,
however, are poorly understood. In this study, computational methods including text- and data-mining have been used to
select and prioritize candidate aetiological genes for salt-sensitive hypertension. Additionally, we have compared allele
frequencies and copy number variation for single nucleotide polymorphisms in candidate genes between indigenous
Southern African and Caucasian populations, with the aim of identifying candidate genes with significant variability
between the population groups: identifying genetic variability between population groups can exploit ethnic differences in
disease prevalence to aid with prioritisation of good candidate genes. Our top-ranking candidate genes include parathyroid
hormone precursor (PTH) and type-1angiotensin II receptor (AGTR1). We propose that the candidate genes identified in this
study warrant further investigation as potential aetiological genes for salt-sensitive hypertension.
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Introduction
Essential hypertension is a complex disease characterised by a
sustained elevation in blood pressure with no known underlying
medical or biological cause. The heritability of hypertension is
thought to range from 30% to 60%, with variable clinical presen-
tation and drug response due to multiple contributory genes,
genetic/ethnic heterogeneity and environmental effects [1,2].
Genome-wide linkage, association, and candidate gene studies
in patients and animal hypertension models have identified an
array of associated variants for hypertension that include sodium
channels, the sympathetic nervous system and adrenergic path-
ways, and the renin-angiotensin-aldosterone system (reviewed in
[1,3,4]).
Although high dietary salt intake may be associated with
hypertension, blood pressure response to salt in individuals is
heterogeneous and most likely due to the genetic background of
individuals. Thus, in some cases, hypertension appears to be salt-
sensitive and reduction of dietary salt results in a significant
decrease in blood pressure, and conversely salt resistance if there is
little or no change. The underlying genetics of this type of
hypertension, however, have not been fully elucidated [5].
Evidence to date suggests the involvement of variants of sodium
channels, renal ion channels, the mineralocorticoid receptor, and
related proteins affecting synthesis and levels of mineralocorticoids
(reviewed in [2]). Additional proposed disease variants include
those of the a-adducin gene (increasing sodium/potassium pump
activity), the glucagon gene, (reducing cAMP production and
impairing natriuresis), the serum- and glucocorticoid-regulated
kinase (SGK1) gene (enhancing aldosterone–induced expression of
sodium channels) [6], and genes involved in arachidonic acid
metabolism [7] (reviewed in [8]). Additionally, variation in the
Cyp4A10 gene, a member of the cytochrome P450 family involved
in the functional regulation of sodium channels, may cause salt-
sensitive hypertension [9].
Salt-sensitive hypertension appears to be more prevalent in
people of indigenous African origin, for example it was found in
73% of African-American hypertensive patients when compared
with 51% of the hypertensive population and 26% of normoten-
sive individuals [10,11]. Of interest, it has also been shown that
Caucasians secrete a water load more rapidly than indigenous
Africans, perhaps due to a difference in renal water handling. This
may also have an impact on occurrence of salt-sensitive
hypertension in the two populations [12]. In a study from South
Africa, suppressed plasma renin activity (an index of salt sensitivity)
was significantly lower in both normotensive and hypertensive
indigenous African patients compared to Caucasians despite
comparable sodium intake. This was particularly evident in
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Africans have a plasma renin activity ,1.1 ng/ml/hr [13]. We
have previously shown a relationship of the R563Q mutation of
the SCNN1b gene with hypertension, but the prevalence of this
SNP in the hypertensive population is 5% and ,1% in
normotensives and cannot account for the suppressed plasma
renin activity in 70% of indigenous Africans [14].
Although it can be shown that certain risk factors and diseases
vary as a function of ethnicity, it is difficult to translate this
effectively into therapeutics until the underlying genotypes are
better understood. The ultimate aim would be to optimise
treatment based solely on genotype and regardless of ethnicity.
However in the first instance, population diversity and ethnic
differences in disease risk present an avenue of research towards
understanding the underlying disease genetics [15].
Computational identification of most likely etiological genes can
facilitate more efficient identification of genes of diagnostic,
prognostic and therapeutic value by presenting strong candidates
for future empirical research. The aim of this study, therefore, is to
use computational approaches to prioritize and present most likely
disease gene candidates for salt-sensitive hypertension, for further
empirical analysis by translational researchers. In this study, we
have used gene functional annotation associated with hyperten-
sion and salt-sensitivity to predict and rank novel candidates for
salt-sensitive hypertension. Our analysis uses a computational
approach that combines text-mining of PubMed abstracts for
potentially relevant genes, and extensive mining of gene anno-
tation data. We have then analysed Affymetrix single nucleotide
polymorphism (SNP) data in a total of 126 indigenous South
African individuals, spanning five distinct indigenous South
African population groups, for top-scoring candidate genes from
the computational analysis. We have compared allele frequencies
at all SNPs assayed in indigenous Southern Africans, with those in
the Caucasian population assayed in the HapMap project [16].
We have also looked for variation in the copy number of candidate
genes between the different population groups. Our intention is to
prioritise by computational approaches most likely candidate
genes for salt-sensitive hypertension; and to prioritise further those
candidates that are sufficiently different between the South African
and Caucasians to potentially underlie susceptibility to salt-
sensitive hypertension in indigenous Southern African populations.
Methods
Selection of candidate genes by Gene Ontology (GO)
annotation
Data was accessed from the Ensembl database (Ensembl_
mart_47) [17]. GO annotations were selected using AmiGO ([18],
www.geneontology.org) to reflect a range of pathways and
functions. An overview of the functions and pathways included
is shown in Table 1 (1–9). The full descriptions of all GO terms
used are shown in Supplementary Data File S1.
Selection of candidate genes by text mining of PubMed
abstracts
Text-mining was used to identify gene names that most
frequently occur in conjunction with a variety of salt-sensitive
hypertension-related terms. These terms are described in Table 1
(10–11). The PubMed queries were made on March 24, 2008. Six
queries (Table 1) retrieved in total 22,966 PubMed abstracts that
were analyzed by Dragon Explorer System (DES), a licensed tool
of OrionCell http://www.orioncell.org. DES uses proprietary and
manually curated dictionaries of entities related to various topics
and maps them to the text documents for extracting potentially
relevant information from these documents. The functioning of
the text-mining modules of DES is based on similar concepts as
described in [19]and [20], and has been previously applied in the
creation of a DDESC database of sodium channels [21] and for
parts of the DDOC database [22] and DDEC databases of
esophageal cancer [23]. In this study, DES is applied with the
dictionary of ‘‘human genes and proteins’’ that contains over
300,000 variants of names, symbols, aliases, previous names and
previously used symbols of genes and proteins, compiled from the
literature and public databases. In the study by Sagar et al. the
accuracy of DES systems to correctly identify human genes and
proteins in PubMed abstracts was estimated to be with sensitivity
of 81%, specificity of 96% and F-measure of 88% [21]. After gene
and protein names have been identified, the respective Entrez-
Gene IDs are determined, which eliminates naming redundancies.
These genes have been used for further analysis in our study.
Scoring and ranking of candidate genes
Gene lists were generated that fulfilled the various categories as
described above and in Table 1. For each gene included, a
cumulative score was assigned for every category assayed that was
met by the gene. For most categories, the gene was assigned a
score of one if the category was met. However for some of the
terms found in PubMed abstracts, this score was divided such that
a score of 0.5 was assigned if the gene co-occurred with the
independent components of the given phrase. An additional score
of 0.5 was subsequently only assigned if certain of these com-
ponents occurred together as a complete phrase. For example a
gene co-occurring with ‘‘sodium’’ and ‘‘reabsorption’’ and ‘‘kidney’’
will score 0.5, whereas a gene co-occurring with ‘‘sodium
reabsorption’’ and ‘‘kidney’’ will score (0.5+0.5)=1.
Selection of SNPs by population-specific allele
frequencies
This study was reviewed by the Ethics Committee of the
University of Cape Town and received research ethics approval
(REC REF 305/2009: ‘‘Genome Wide Microarray Analysis of
Southern African Human Populations’’). For five self-identified
ethnic/linguistic indigenous South African population groups,
allele frequencies in the genetic material from a total of 126
individuals were analysed using the Affymetrix GenomeWideSNP
6.0 Array (Homo sapiens, Genome assembly: NCBI Build 36,
UCSC hg18, covering 906 600 SNPs and more than 946 000
probes for the detection of copy number variation). All individuals
were collected as unrelated and confirmed that their parents and
grandparents were from the same ethnic groups. DNA was
prepared from peripheral blood by standard phenol–chloroform
procedures and shipped to Affymetrix (http://www.affymetrix.
com) for genotyping (full data under preparation for publication).
Genotypes were called using the Birdseed algorithm distributed
with Affymetrix Power Tools [24]. Quality of CEL files was
assessed with the Dynamic Model (DM) algorithm, and only
individuals (CEL files) with QC.90 were included in downstream
genotyping calling. Population groups included are, with number
of individuals in parentheses, Khoisan (22), Xhosa (34), Hererro
(25), Setswana (25) and Zulu (20). For each candidate gene, all
SNPs analysed using the Affymetrix array were selected (a total of
1079 SNPs, full data in supplementary data file S2), and the allele
frequencies calculated across the South African populations. All of
these South African allele frequencies for each South African
population group were then compared to the allele frequencies
for these SNPs as reported for Caucasians by the HapMap pro-
ject [16]. Information regarding the nature of each SNP was
Candidate Hypertension Genes
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wherever such data was available.
Analysis of Copy Number Variation
Copy number analysis was performed with the Birdsuite
package (version 1.5.2) [26], which uses hybridisation intensities
of both SNP and CN probes to provide greater coverage and
enable the detection of novel as well as known copy-number
variations. Default settings, as described in [26] were used, with
the exception that copy number models were not limited to
known variants. Reference CEL files for the HapMap CEU
population were processed using the same configuration. In
addition to the previously mentioned samples filtered due to low
quality, two Zulu samples were identified as having high copy
number variance and removed. For each gene and its flanking
sequence, a heatmap was generated to indicate copy number of
probes assayed.
Statistical Analysis
The significance level of differences in allele frequencies for the
same SNPs between the different populations was calculated using
the Fishers Exact Test, using Python scripting with the RPy
module (http://rpy.sourceforge.net/) and R statistical software
[27].
Table 1. Criteria for terms used to identify candidate genes.
Genes involved in regulatory pathways, and second messenger/signalling pathways, as annotated with GO terms Genes Score
1. Renin-angiotensin-aldosterone pathway 183 1
i.‘angiotensin’-containing GO terms
ii. ‘renin’-containing GO terms
iii. ‘aldosterone’-containing GO terms
2. Renin-angiotensin-aldosterone pathway second messengers
i. cAMP/protein kinase- associated GO terms
ii. Calcium signalling – related GO terms
iii. Protein Kinase A – related GO terms
3. Adrenergic or sympathetic nervous system 1707 1
i. ‘‘adrenergic’’- containing GO terms
ii. ‘‘sympathetic’’-containing GO terms
4. Adrenergic or sympathetic nervous system second messengers
i. GTP-binding – related GO terms
5. Brain and atrial natriuretic peptide 17 1
i. natriuretic peptide receptor activity –related GO terms
ii. regulation of systemic arterial blood pressure by atrial natriuretic peptide – related GO terms
6. Brain and atrial natriuretic peptide signalling-related terms
i. cGMP/Protein Kinase G – related GO terms
7. Dopaminergic system 210 1
i. ‘dopamine receptor’– containing GO terms
8. Dopaminergic system signalling-related terms
i. ‘dopamine receptor signaling’ – related GO terms
ii. adenylate-cyclase/dopamine receptor/G-protein – related GO terms
iii. cAMP-dependent protein kinase–related GO terms
iv. phospholipase C-related GO terms
Gene product is part of sodium pump or channel
9. ‘‘sodium channel’’- containing GO terms 49 1
Gene influences sodium excretion or reabsorption in the kidney
10. Gene names co-occurring with sodium excretion/reabsorption/kidney terms in PubMed abstracts
i. Genes co-occurring with ‘‘sodium excretion’’ and ‘‘kidney’’ [4173 PubMed hits] 59 0.5
ii. Genes co-occurring with ‘‘sodium reabsorption’’ and ‘‘kidney’’ [1568 PubMed hits] 84
iii. Genes co-occurring with ‘‘sodium’’ and ‘‘reabsorption’’ and ‘‘kidney’’ [4643 PubMed hits] 140 0.5
iv. Genes co-occurring with ‘‘sodium’’ and ‘‘excretion’’ and ‘‘kidney’’ [9799 PubMed hits] 99
Activity of gene is associated with low renin and with variable aldosterone levels
11. Gene names co-occurring with low renin/variable aldosterone levels in PubMed abstracts
i. Genes co-occurring with ‘‘low renin’’ [997 PubMed hits] 24 1
ii. Genes co-occurring with ‘‘aldosterone levels’’ [1786 PubMed hits] 41
doi:10.1371/journal.pone.0012989.t001
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Identification of candidate genes
In total, 2057 unique genes were included across all gene lists,
and were used as the primary set of candidate genes. Each of these
was then assayed for the various characteristics (see Table 1), by
both text-mining and GO annotation, and assigned a cumulative
score, shown in Table 2. The genes were ranked by this score, and
the top scoring candidates prioritised as most likely candidate
disease genes (scoring for all candidates shown in Supplementary
Data File S3). The top scoring candidates were curated to exclude
any spurious results. The top ranking genes were PTH -
Parathyroid hormone precursor and AGTR1 - Type-1 angiotensin
II receptor. A selection of additional likely candidates was made
from the genes ranked in the top twenty positions, as shown in
Table 3 (full set of top candidates shown in Supplementary Data
File S4).
Comparative analysis of SNP frequencies in candidate
genes, between populations
A total of 1079 SNPs were selected from the Affymetrix data as
associated with the prioritised candidate genes, falling either
within the genes or within 100 000 bp either upstream or
downstream of the gene (Supplementary Data File S2) (the
SCNN1b gene was not included in this analysis as it was not one of
the prioritised genes). Of these, 303 had allele frequencies that
were significantly different between Caucasian and all indigenous
South African populations at a threshold of p,0.05. There were
159 SNPs that had allele frequencies that were significantly
different at a threshold of p,0.001. The categories and numbers
of SNPs selected are shown in Table 4. Additionally, the numbers
of SNPs falling within the coding region of the gene and not the
flanking sequence are shown. These were distributed across the
candidate genes as shown in Table 5, and results for a selection of
genes are shown in Figure 1 (SNP distribution in all genes and
flanking sequences are shown in supplementary file S5). The
distribution of SNPs within the genes and excluded from the
flanking sequence are also shown.
Analysis of Copy Number Variation
Variation in copy number of individual probes is evident, as
shown on the heatmaps generated; however there was no evidence
of a change in copy number at the gene level for any of the
candidate genes analysed (supplementary data file S6).
Discussion
The high ranking genes in the candidate gene list included
several previously identified causative genes for hypertension. The
top scoring AGTR1 gene has been extensively implicated in
controlling blood pressure and volume in the cardiovascular
system and pharmacologic agents that interrupt the action of
angiotensin II action by antagonizing the AGTR1 receptor are
highly successful in the treatment of angiotensin II-dependent
hypertension [28]. AGT, AGTR1, ACE and REN are all members
of the renin-angiotensin-aldosterone pathway (as shown in www.
pharmgkb.org, the ACE inhibitor pathway). ACE inhibitors and
AGTR1-blocking drugs are already extensively exploited as
therapy for hypertension. Given that these genes are well
annotated and form the foundation of the characteristics used to
select new candidates, it is unsurprising that they are highly scored
in the analysis and act as an internal control showing that the
selective process is accurate. The same is true of NPPA- Atrial
natriuretic peptide [29], although interestingly this gene was not
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rather by association in PubMed abstract with terms including
sodium reabsorption/excretion, low renin and aldosterone levels.
Despite our previous description of the association of hyper-
tension with the R563Q mutation, the SCNN1b gene was not
identified as a good candidate gene. It only fulfilled one of the
characteristics that we used to prioritise candidates (‘‘sodium
transport’’), and therefore was not assigned a high priority as a
candidate gene. The focus of this computational analysis is to
synthesise various sources of information to highlight less obvious
good candidates, such as PTH, rather than selecting more obvious
candidates such as SCNN1b based only on a one-dimensional
analysis of the direct link between gene and disease. The
limitations of detecting genetic associations with hypertension
must also be noted, whereby detection of common variants with
small effects is more likely than detection of a rare variant
dominant effect like the R563Q mutation. [30].
PTH is also top-scoring alongside AGTR1. It has a less defined
role in essential hypertension, which makes it an interesting
novel candidate for salt-sensitive hypertension. Several lines of
research support a potential role for PTH in the pathogenesis of
salt-sensitive hypertension. It has been proposed that the level
of PTH may be raised as a secondary response to hypertension
[31,32], as a response to dysregulated sodium excretion from
the kidney. It has, however, also been shown that administra-
tion of PTH to healthy volunteers under normal glycaemic
conditions, in the presence of controlled circulating insulin
levels, results in a significant and consistent increase in blood
pressure and concurrently in ionised calcium concentration.
The increase in blood pressure was strongly correlated to
changes in calcium ion concentration [33]. Similarly, hyper-
calcaemia and hypertension were observed in response to
administration of supraphysiological levels of PTH [[34].
Further observations have been made previously that in
uraemic patients with secondary hyperparathyroidism, in
patients with secondary hyperparathyroidism, and in geneti-
cally pre-hypertensive patients a positive correlation is found
between blood pressure and PTH/Calcium ion concentrations
[35,36,37]. In humans salt-induced increases in blood pressure
have been linked to increases in intracellular free calcium [38].
The calcium binding to the Ca-sensing receptor expressed in
the thick ascending limb inhibits the Na,K, 2CL cotransporter,
Table 3. Candidate genes selected for further analysis.
Gene Symbol Ensembl ID Description
PTH ENSG00000152266 Parathyroid hormone precursor (Parathyrin) (PTH) (Parathormone)
AGTR1 ENSG00000144891 Type-1 angiotensin II receptor (AT1) (AT1AR) (AT1BR).
EDNRA ENSG00000151617 Endothelin-1 receptor precursor (Endothelin A receptor) (ET-A) (hET- AR) (ETA-R).
AGT ENSG00000135744 Angiotensinogen precursor (Serpin A8) [Contains: Angiotensin-1 (Angiotensin I) (Ang I); Angiotensin-2
(Angiotensin II) (Ang II); Angiotensin-3 (Angiotensin III) (Ang III) (Des-Asp[1]-angiotensin II)].
REN ENSG00000143839 Renin precursor (EC 3.4.23.15) (Angiotensinogenase)
HCN4 ENSG00000138622 Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4
EDNRB ENSG00000136160 Endothelin B receptor precursor (ET-B) (Endothelin receptor Non- selective type).
HCN2 ENSG00000099822 Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 2 (Brain cyclic nucleotide-
gated channel 2) (BCNG-2).
ANG ENSG00000214274 Angiogenin precursor (EC 3.1.27.-) (Ribonuclease 5) (RNase 5).
NPPA ENSG00000175206 Atrial natriuretic factor precursor (ANF) (Atrial natriuretic peptide) (ANP) (Prepronatriodilatin) (CDD-ANF)
[Contains: Cardiodilatin-related peptide (CDP)].
INS ENSG00000129965 Insulin precursor [Contains: Insulin B chain; Insulin A chain]
ACE ENSG00000159640 Angiotensin-converting enzyme
EDN1 ENSG00000078401 Endothelin-1 precursor (Preproendothelin-1) (PPET1) [Contains: Endothelin-1 (ET-1); Big endothelin-1].
doi:10.1371/journal.pone.0012989.t003
Table 4. The categories and numbers of all SNPs selected.
With 100000 bp flanking sequence Without flanking sequence
SNP Type P,0.05 P,0.001 P,0.05 P,0.001
39 Downstream 18 13 1 1
39 U T R 53 10
59 Upstream 14 6 0 0
Coding synonymous 3 3 2 2
Coding nonsynonymous 1* 0 0 0
Intronic 104 43 43 22
Undefined 158 91 0 0
*This falls in a neighbouring gene, and not the candidate gene of interest.
doi:10.1371/journal.pone.0012989.t004
Candidate Hypertension Genes
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blood pressure [39]. Finally, the prevalence of hypertension is
known to be high in patients with primary hyperparathyroid-
ism [40].
Additionally, PTH levels are found to be elevated in African
American individuals when compared to those of Caucasian
descent [41], which further supports a role for PTH as an
underlying causative gene for salt-sensitive hypertension in
indigenous South African patients. However it is possible that
this is an indirect association as these elevated levels may be the
result of vitamin D insufficiency, due to less sun-stimulated vitamin
D synthesis in dark-skinned people [41,42].
Finally, in a prospective study, Taylor et al. examined the
association between plasma intact PTH levels and the risk of
incident hypertension in 481 men without baseline hypertension,
and suggested that plasma levels of intact PTH (even within ranges
considered normal) are positively and independently associated
with a higher risk of incident hypertension. These authors
proposed that PTH could potentially serve as a novel target for
the prevention of hypertension [43], supporting its ranking as a
primary candidate gene in our study. This may also have
implications for therapy as these patients could potentially respond
better to calcium channel blockers.
Of the additional high-scoring candidates, some have been
previously directly associated with hypertension and salt-
sensitivity. Candidates EDNRA, EDN1 and EDNRB function
together in a regulatory pathway with endothelin-converting
enzyme ECE1, which has been implicated in essential
hypertension. Additionally, Rothermund et al. proposed a role
for EDNRA and EDNRB in salt-sensitive hypertension [44]. Our
study suggests that these genes are good candidates and should
be revisited for a potential role in salt-sensitive hypertension.
The association between the insulin gene, INS,a n dh y p e r t e n -
sion has been well documented. There is extensive cross-talk
between insulin and angiotensin II regulating the metabolic and
circulatory systems, with effects at both the extracellular level
whereby ACE controls angiotensin II synthesis and interferes
with insulin signalling through angiotensin II regulation and
accumulation of bradykinin; and at the intracellular level
whereby signal transduction pathways are affected (reviewed in
[45,46]). Clinically, the association between insulin resistance
and pre-hypertension has been demonstrated [47], and it has
also been proposed that insulin promotes renal sodium
retention ([48] and references therein). Therefore insulin is a
good candidate for salt-sensitive hypertension, as it has been
implicated in both hypertension and sodium retention.
Other high-scoring candidates have not been shown previously
to have a direct role in hypertension, although they do have roles
in vascular and heart physiology, and have been associated with
other diseases. HCN2 and HCN4 are hyperpolarisation-activated
cation channels of the HCN gene family, and contribute to
spontaneous rhythmic activity in both heart and brain. Expression
of HCN4 is predominantly in the heart, as well as the thalamus
and the developing central nervous system. Mutations in HCN4
have been associated with the cardiac disease, sinus bradycardia
(OMIM #163800). The gene product of ANG, the angiogenin
gene, is an inducer of neovascularization, and the RNase activity
of ANG is important for its angiogenic activity. It is induced by
hypoxia to elicit angiogenesis and is expressed in motor neurons;
mutations in ANG are associated with the neurodegenerative
disease amyotrophic lateral sclerosis in some populations (OMIM
# 611895).
The computational approach we have used has selected both
hypertension-associated and novel candidate genes for salt-
sensitive hypertension. We have used a variety of gene
characteristics and functional annotations to select most likely
candidates for this disease. Although text- and data-mining do rely
on existing information to inform the results, such computational
approaches are able to synthesise huge volumes of existing data
both through the biomedical literature, and gene annotation in
genomic databases. The systematic analysis and categorisation of
such volumes of existing data allow novel connections and
inferences to be made computationally. The scoring system is
based on the premise that a candidate gene selected by multiple
sources of evidence is a better candidate than one selected by fewer
lines of evidence (as previously demonstrated in [49,50,51]), and
therefore allows objective weighting of the value and extent of such
inferences. In general, the ability of our method to identify a
Table 5. The numbers of SNPs selected for each candidate gene.
Flanking sequence included Gene sequence only
Gene Name
Gene
Length (bp)
Total SNPs
Assayed
SNPs selected
p,0.05
SNPs selected
p,0.001
Total SNPs
Assayed
SNPs selected
p,0.05
SNPs selected
p,0.001
HCN4 47242 49 7 2 8 0 0
HCN2 27264 17 4 3 1 1 1
INS 32100 46 9 3 9 1 1
NPPA 2633 59 11 4 3 0 0
EDNRB 24126 82 21 6 16 4 1
PTH 3965 48 14 9 1 1 1
AGT 11667 131 27 9 9 0 0
ACE 44769 45 16 9 19 4 2
ANG 9571 130 22 15 8 0 0
REN 11517 110 35 16 15 2 2
EDN1 6800 124 38 24 9 5 3
EDNRA 63980 101 42 27 42 18 9
AGTR1 45123 137 57 32 25 11 5
doi:10.1371/journal.pone.0012989.t005
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PLoS ONE | www.plosone.org 6 September 2010 | Volume 5 | Issue 9 | e12989Figure 1. Examples of distribution of SNPs with significantly different allele frequencies when comparing indigenous Southern
African and Caucasian populations (all genes shown in supplementary data file S5). Gene exon structure (bold vertical bars),
chromosome and base pair position (horizontal axis) are shown. Each black cross represents a SNP with allele frequencies that differ between
Caucasian and South African populations at the level of significance indicated, and the grey crosses represent all SNPs analysed. A. EDNRA (many
SNPs within the gene) B. AGT (a few SNPs within the gene, most SNPs in flanking regions); C. ANG (no SNPs within the gene); D. PTH (few SNPs
assayed within the gene).
doi:10.1371/journal.pone.0012989.g001
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PLoS ONE | www.plosone.org 7 September 2010 | Volume 5 | Issue 9 | e12989number of genes already implicated in hypertension indicates that
the methodology we have used is sound, and that the
characteristics by which we have prioritised candidates are
appropriate. Our method, however, has also highlighted novel
candidates for which disparate existing knowledge recorded in the
biomedical literature and in functional gene annotation has not
previously been collated to support a role in salt-sensitive
hypertension.
The sample set of indigenous South Africans is relatively small,
and because of this, the information about allele frequency and
copy number variation is presented here as preliminary data.
Because of the high incidence of hypertension in indigenous South
Africans (for example up to 25% in urban Zulu individuals [52]),
of which up to 50% show suppressed plasma renin activity, an
indirect measure of salt sensitivity [13], it is however likely that a
genetic predisposition to this disease is represented in a fair
proportion of the population, and that the evidence for this can be
found in our sample set when compared to Caucasians. Such
information can be invaluable to the researcher designing studies
to identify the underlying genetics of salt-sensitive hypertension: as
with all candidate disease gene studies, we present here a
prioritisation of alleles for further investigation – only further
empirical analysis of appropriately sized sample sets would be able
to confirm the association of particular alleles with salt-sensitive
hypertension.
It is difficult to make a direct comparison between the numbers,
positions and types of SNPs identified for each candidate gene, as
the gene sizes and total number of SNPs are so varied. The
distribution of SNPs within candidate genes can be described in
several approximated categories, and examples are shown in
Figure 1. In some genes, there are no selected SNPs falling within
the gene itself despite many SNPs being assayed in those regions,
and those in flanking sequences are fairly distant from the gene –
these are AGT, ANG, HCN4 and NPPA. In some, a few SNPs are
selected within and close to the gene, although many more SNPs
were assayed than selected in these regions – these are REN, ACE,
EDNRB and INS. We propose that these candidates that show
fewer differences in allele frequency are less likely to underlie the
salt-sensitive hypertension that is seen in indigenous Southern
African populations. In a few candidates, many of the assayed
SNPs were selected falling within or close to the gene – these are
EDNRA, EDN1 and AGTR1. Finally, in a few of the candidates,
few SNPs were assayed within or close to the gene, although these
were generally selected as having significantly different alleles
between the populations – these are HCN2, and the primary
candidate PTH. The two latter categories contain candidates that
appear to have substantial differences in allele frequencies between
Caucasian and the indigenous Southern African populations, and
as such are more likely to contain variants that are responsible for
the salt-sensitive hypertension that is prevalent in the indigenous
Southern African population. Our analysis of copy number
variation did not suggest that the candidate genes investigated
here have any alteration in copy number at the gene level in either
of the population groups. Copy number variation of these genes is
therefore unlikely to underlie the salt-sensitive hypertension that is
prevalent in the indigenous Southern African populations
(although it is interesting to note that the heatmaps generated
for the genes AGTR1 and INS do show evidence of population-
specific variation at sites within the genes - see supplementary data
file S6).
The selection of top-scoring candidates in this study is
inevitably affected by some inherent bias: appropriate genes
that have more extensive annotations are more likely to be
selected in the study than those that have not yet been analysed,
so it is more difficult to select entirely novel candidates.
However, we have aimed to combine existing knowledge about
hypertension and salt sensitivity to draw new conclusions about
candidate genes for salt-sensitive hypertension. Computational
analysis thus allows the synthesis of existing information to make
novel predictions.
Due to the population-specific nature of salt-sensitive hyper-
tension, we propose that the SNPs in the prioritised candidate
genes that show significantly different allele frequencies between
Caucasian and indigenous African populations provide good
targets for further clinical and empirical research. We provide
here a list of good candidate genes and alleles related to salt-
sensitive hypertension that have been selected and prioritised by
computational methods. These prioritized genes may have a
significant contribution to the occurrence of salt-sensitive
hypertension, and thus warrant further investigation by transla-
tional researchers.
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Data File S1 GO Terms used for the Selection of Candidate
Genes for Salt-Sensitive Hypertension.
Found at: doi:10.1371/journal.pone.0012989.s001 (0.03 MB
PDF)
Data File S2 All SNPs assayed.
Found at: doi:10.1371/journal.pone.0012989.s002 (0.08 MB
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Data File S3 Final Scoring matrix for all genes.
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Data File S4 Ensembl IDs, HUGO symbols and descriptions of
all top candidates.
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PDF)
Data File S5 Distribution of SNPs with significantly different
allele frequencies when comparing Black South African and
Caucasian populations. Each black cross represents a SNP with
allele frequencies that differ at the indicated significance, between
Caucasian and South African populations. Grey crosses indicate
all SNPs assayed. Gene name, chromosome and position are
shown along the horizontal axis; Gene exons are shown as vertical
black bars.
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Data File S6 Heatmaps showing copy number variation analysis
for candidate genes. Red shading shows a deletion at that position,
blue shading shows a copy number gain at that position. HUGO
gene symbol is shown. Chrm=chromosome. Green lines denote the
gene start and end. Horizontal axis shows position on
the chromosome. Vertical axis shows the individuals from each
population: CEU=HapMap Central European population, XHS=
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population, ZUL=Zulu population, KHS=Khoisan population.
Found at: doi:10.1371/journal.pone.0012989.s006 (3.53 MB
PDF)
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